Venous malformation: Risk of progression during childhood and adolescence

Annals of Plastic Surgery

Volumn 68, Issue 2, 2012, Pages 198-201

  Hassanein, Aladdin H ^a   Mulliken, John B ^a   Fishman, Steven J ^a   Alomari, Ahmad I ^a   Zurakowski, David ^a   Greene, Arin K ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adolescent; anomaly; childhood; malformation; pediatric; progression; vascular; venous; VM

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL MALFORMATION; DISEASE COURSE; FEMALE; HUMAN; INFANT; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEWBORN; PATHOLOGY; PREGNANCY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL; VEIN;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREGNANCY; RETROSPECTIVE STUDIES; RISK; VASCULAR MALFORMATIONS; VEINS; YOUNG ADULT;

EID: 84856590609     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e31821453c8     Document Type: Review

References (42)

1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412-422. (Pubitemid 12191292)
2. Enjolras O, Ciabrini D, Mazoyer E, et al. Extensive pure venous malforma-tions in the upper or lower limb: a review of27 cases. JAm Acad Dermatol. 1997;36:219-225. (Pubitemid 27078915)
3. Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140:971-976. (Pubitemid 39062648)
4. Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malforma-tions. Nat Genet. 2009;41:118-124.
5. Vikkula M, Boon LM, Carraway KL, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996;87:1181-1190. (Pubitemid 27010102)
6. Berenguer B, Burrows PE, Zurakowski D, et al. Sclerotherapy ofcraniofacial venous malformations: complications andresults. Plast Reconstr Surg. 1999; 104:1-11.
7. Upton J, Coombs CJ, Mulliken JB, et al. Vascular malformations of the upper limb: a review of270 patients. JHand Surg Am. 1999;24:1019-1035. (Pubitemid 29449287)
8. Hein K. Mulliken JB, Kozakewich HP, et al. Venous malformations of skeletal muscle. Plast Recontr Surg. 2002;110:1625-1635. (Pubitemid 35470439)
9. Mulliken JB Young AE, eds. Vascular Birthmarks: Hemangiomas and Malformations. Philadelphia, PA: WB Saunders; 1988.
10. Marler JJ, Fishman SJ, Kilroy SM, et al. Increased expression ofurinary matrix metalloproteinases parallels the extent and activity ofvascular anom-alies. Pediatrics. 2005;116:38-45.
11. Liu A, Mulliken JB, Zurakowski D, et al. Extracranial arteriovenous malfor-mations: natural progression and recurrence after treatment. Plast Reconstr Surg. 2010;125:1185-1194.
12. Styne DM. Normal and abnormal age ofonset ofsecondary sexual develop-ment In: Fingberg L, Kleinman RE, eds. Saunders Manual of Pediatric Practice. 2nd ed. Philadelphia, PA: Saunders; 2002:830.
13. Irwin CE, Shafer M, Moscicki A. The adolescent patient. In Rudolph CD, Rudolph AM, eds. Rudolph's Pediatrics. 21st ed. New York, NY: Mc Graw-Hill; 2003:223.
14. Altman DG. Comparing groups-categorical data. In: Altman DG, eds. Practical Statistics in Medical Research. 1st ed. London, United Kingdom: Chapman and Hall; 1991:229-271.
15. Wilson EB. Probable inference, the law ofsuccession, and statistical infer-ence. JAm Stat Assoc. 1927;22:209-212.
16. Newcombe RG. Two-sided confidence intervals for the single proportion: comparisonofsevenmethods. Stat Med. 1998;17:857-872. (Pubitemid 28185165)
17. Notelet L, Houtteville JP, Khour S, et al. Proliferating cell nuclear antigen (PCNA) in cerebral cavernomas: an immunohistochemical study in 42 cases. Surg Neurol. 1997;47:364-370. (Pubitemid 27157505)
18. Sure U, Freman S, Bozinov O, et al. Biological activity of adult cavernous malformations: a study of56 patients. JNeurosurg. 2005;102:324-347.
19. Bicer A, Gucu B, Ozkan A, et al. Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vas-cular malformations. J Clin Neurosci. 2010;17:232-236.
20. Duyka LJ, Fan CY, Coviello-Malle JM, et al. Progesterone receptors identi-fied in vascular malformations of the head and neck. Otolaryngol Head Neck Surg. 2009;141:491-495.
21. Johannisson E, Oberholzer M, Swahn ML, et al. Vascular changes in the human endometrium following the administration of the progesterone antag-onist RU486. Contraception. 1989;39:103-117. (Pubitemid 19022942)
22. Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Per-spect. 2000;108:785-790.
23. Hyder SM, Nawaz Z, Chiappetta C, et al. Identification offunctional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 2000;60:3183-3190. (Pubitemid 30407915)
24. Mueller MD, Vigne JL, Minchenko A, et al. Regulation of vascular endo-thelial growth factor (VEGF) gene transcription by estrogen receptors alpha andbeta. Proc Natl Acad Sci USA. 2000;97:10972-10977.
25. Heryanto B, Rogers PA. Regulation ofendometrial endothelial cell prolifer-ation by oestrogen and progesterone in the ovariectomized mouse. Reproduc-tion. 2002;123:107-113. (Pubitemid 34100568)
26. Nayak NR, Brenner RM. Vascular proliferation and the vascular endothelial growth factor expression in the rhesus macaque endometrium. J Clin Endo-crinol Metab. 2002;87:1845-1855. (Pubitemid 34615279)
27. Kayisli UA, Luk J, Guzeloglu-Kayisli O, et al. Regulation of angiogenic activity of human endometrial endothelial cells in culture by ovarian steroids. J Clin Endocrinol Metab. 2004;89:5794-5802. (Pubitemid 39518473)
28. Joseph IB, Nelson JB, Denmeade SR, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostate tissue. Clin Cancer Res. 1997;3:2507-2511. (Pubitemid 28133175)
29. Haggstrom S, Lissbrant IF, Bergh A, et al. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. JUrol. 1999;161:1620-1625. (Pubitemid 29420852)
30. Stewart RJ, Panigrahy D, Flynn E, et al. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol. 2001;165:688-693. (Pubitemid 32060501)
31. Lissbrant I, Lissbrant E, Persson A, et al. Endothelial cell proliferation in male reproductive organs of adult rat is high and regulated by testicular factors. Biol Reprod. 2003;68:1107-1111. (Pubitemid 36359097)
32. Lissbrant I, Hammarsten P, Lissbrant E, et al. Neutralizing VEGF bioactivity with a soluble chimeric VEGF receptor protein flt(1-3)Ig G inhibits testoster-one stimulated prostate growth in castrated mice. Prostate. 2004;58:57-65. (Pubitemid 38057989)
33. Gould J, Aramburo C, Capdevielle M, et al. Angiogenic activity of anterior pituitary tissue and growth hormone on the chick embryo chorio-alloantoic membrane: a novel action of GH. Life Sci. 1995;56:587-594.
34. Struman I, Bentzien F, Lee H, et al. Opposing actions ofintact and N-terminal fragments of the human prolactin/growth hormone family members ofangio-genesis: an efficient mechanism for the regulation ofangiogenesis. Proc Natl Acad Sci USA. 1999;96:1246-1251. (Pubitemid 29098436)
35. Thorey IS, Hinz B, Hoeflich A, et al. Transgenic mice reveal novel activities of growth hormone in wound repair, angiogenesis, and myofibroblast differ-entiation. JBiol Chem. 2004;279:26674-26684. (Pubitemid 38798825)
36. Mazoyer E, Enjolras O, Laurian C, et al. Coagulation abnormalities associ-ated with extensive venous malformation of the limbs: differentiation from Kassabach-Merritt syndrome. Clin Lab Haematol. 2002;24:243-251. (Pubitemid 34989256)
37. Homans J. Diseases of the veins. N Engl J Med. 1944;231:51-60.
38. Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. J Vasc Interv Radiol. 2004;15:431-435.
39. Choi DJ, Alomari AI, Chaudry G, et al. Neurointerventional management of low-flow vascular malformations of the head and neck. Neuroimaging Clin N Am. 2009;19:199-218.
40. Greene AK, Alomari AI. Management of venous malformations. Clin Plast Surg. 2011;39:89-93.
41. Yamaki T, Nozaki M, Sakurai H, et al. Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liq-uid sclerotherapy in the treatment of symptomatic venous malformations. J Vasc Surg. 2008;47:578-584. (Pubitemid 351258277)
42. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273-286. (Pubitemid 46505878)